<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink">
  <front>
    <journal-meta>
      <journal-title-group>
        <journal-title>V. S. França);</journal-title>
      </journal-title-group>
    </journal-meta>
    <article-meta>
      <title-group>
        <article-title>OntoNeH - Reference ontology for hematologic neoplasms with a focus on Hodgkin Lymphoma, especially the classic type</article-title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <string-name>Vanderléia da Silva França</string-name>
          <xref ref-type="aff" rid="aff0">0</xref>
        </contrib>
        <contrib contrib-type="author">
          <string-name>Henrique Monteiro Cristovão</string-name>
          <email>henrique.cristovao@ufes.br</email>
          <xref ref-type="aff" rid="aff1">1</xref>
        </contrib>
        <contrib contrib-type="author">
          <string-name>Silvia das Dores Rissino</string-name>
          <email>silvia.rissino@ufes.br</email>
          <xref ref-type="aff" rid="aff0">0</xref>
        </contrib>
        <contrib contrib-type="author">
          <string-name>Maria das Graças da Silva Teixeira</string-name>
          <email>maria.teixeira@ufes.br</email>
        </contrib>
        <aff id="aff0">
          <label>0</label>
          <institution>Federal University of Espírito Santo (UFES) - São Mateus</institution>
          ,
          <addr-line>ES -</addr-line>
          <country country="BR">Brazil</country>
        </aff>
        <aff id="aff1">
          <label>1</label>
          <institution>Federal University of Espírito Santo (UFES) - Vitória</institution>
          ,
          <addr-line>ES -</addr-line>
          <country country="BR">Brazil</country>
        </aff>
      </contrib-group>
      <pub-date>
        <year>2011</year>
      </pub-date>
      <volume>000</volume>
      <fpage>0</fpage>
      <lpage>0003</lpage>
      <abstract>
        <p>Cancer is a pathology formed by various diseases characterized by uncontrolled cell proliferation, including Hodgkin's Lymphoma. There's a remarkable advance in methods for diagnosis and treatment with better prognosis. It should be noted that the most appropriate diagnosis and treatment for cancer undergoes a better understanding of the disease itself. In this scenario, artifacts that facilitate and even expand knowledge of the domain are of paramount importance. Thus, the present work uses the SABIO approach and UFO foundational ontology to develop a reference ontology, called OntoNeH (Reference Ontology for Hematological Neoplasms), which has the domain of Cancer Healthcare and its subareas of study, focusing on Oncohematology. Extensive research has been carried out to obtain domain knowledge and Ontology Engineering was applied for the construction of the proposed ontology. As a result, there is a graphical representation of the domain, which can be beneficial for understanding and communicating the subject among those concerned, in addition to serving as a conceptual model for decision-making in a health information system.</p>
      </abstract>
      <kwd-group>
        <kwd>eol&gt;Hodgkin's Lymphoma</kwd>
        <kwd>Conceptual Model</kwd>
        <kwd>Oncohematology</kwd>
        <kwd>Ontology</kwd>
        <kwd>SABIO</kwd>
        <kwd>UFO</kwd>
        <kwd>1</kwd>
      </kwd-group>
    </article-meta>
  </front>
  <body>
    <sec id="sec-1">
      <title>1. Introduction</title>
      <p>
        The word cancer originates from the Greek karkinos, which means crab. It is the name given to a set
of more than 100 diseases, having as a common point the disordered growth of cells, which tend to
invade neighboring tissues and organs [
        <xref ref-type="bibr" rid="ref1">1</xref>
        ]. Cancer is one of the leading causes of death in the world,
being one of the main public health problems worldwide. Among the hundreds of different types of
cancers are those linked to blood cells, such as lymphomas and leukemias.
      </p>
      <p>
        Estimates from the Global Cancer Observatory reveal that there were 19.3 million new cases of
cancer in the world in 2020, with an estimated 544 thousand cases of Non-Hodgkin's Lymphoma, 83
thousand cases of Hodgkin's Lymphoma and 475 thousand cases of Leukemia. In Brazil, in the
threeyear period from 2023 to 2025, 704 thousand new cases of cancer are expected per year. Of these, the
annual estimates for Non-Hodgkin Lymphoma, Hodgkin Lymphoma, and Leukemia are 12040, 3080,
and 11540 new cases, respectively [
        <xref ref-type="bibr" rid="ref2">2</xref>
        ].
      </p>
      <p>Considering the scenario, the interest in identifying, understanding and treating cancer is
increasing. There is a remarkable advance in diagnostic methods, and also the emergence of
innovative treatments and, consequently, better prognosis. It is worth noting that the correct
diagnosis and the most appropriate treatment for cancer depend on a better understanding of the
disease, and the chances of a positive result are directly linked to the rapid action of these activities.</p>
      <p>In this scenario, artifacts that make it possible to facilitate and even expand knowledge of the subject
are of paramount importance. And this is where ontologies come in, because the support for
information organization and retrieval, such as those based on ontological databases, becomes
relevant to deal with the large mass of data produced in Biomedicine related to the topic of interest.</p>
      <p>Thus, this article presents the Reference Ontology for Hematological Neoplasia (OntoNeH), a
domain ontology with the purpose of representing a fragment of the complex Health domain,
focusing on the Oncohematology sub-domain.</p>
      <p>The text was designed to be accessible to both healthcare professionals and a technical Computing
team. For this reason, it was decided not to delve deeply into design decisions but to include brief
explanations of concepts such as UFO, SABiO, OntoUML and Cancer, making it easier for those who
may be unfamiliar with one or both fields to understand.</p>
      <p>The text is structured as follows: Section 1 has an introduction; Section 2 brings a brief theoretical
framework of Ontology and Ontology Engineering, and the methodology used; Section 3 presents a
theoretical review of the domain to be modeled, Oncohematology; Section 4 introduces OntoNeH;
and finally, section 5 contains the final considerations.</p>
    </sec>
    <sec id="sec-2">
      <title>2. Ontology and Ontology Engineering</title>
      <p>
        The term ontology is used in several areas and with different definitions. For the purpose of this
article, the definition is the one that meets the interests of the integration between Computing and
Health, namely: ontology is a "formal and explicit specification of a shared conceptualization" [
        <xref ref-type="bibr" rid="ref3">3</xref>
        ]. In
the taxonomy of classification of knowledge organization systems, according to Zeng [
        <xref ref-type="bibr" rid="ref4">4</xref>
        ] ontology
appears prominently in the highest category as being capable of representing concept models with
complex relationships between objects, including the rules and axioms.
      </p>
      <p>
        There are also several ways of classifying ontologies, one of the best known being proposed by
Guarino, in which the distinction is made by the level of generality of the artifact. The categories
are: (1) top-level ontologies, which describe broader concepts, and are independent of a specific
problem or particular domain (e.g., object and event); (2) and (3) domain ontologies and task
ontologies, describe, respectively, vocabulary related to a specific domain (e.g., disease) or a generic
task or activity (e.g., treatment), and contribute to domain-dependent problem solving; and (4)
application ontologies, which describe concepts dependent on both a domain and a specific task (e.g.,
radiotherapy treatment for Hodgkin's Lymphoma) [
        <xref ref-type="bibr" rid="ref5">5</xref>
        ].
      </p>
      <p>
        Considering the size and complexity that an ontology can reach, Ontology Engineering (EO)
emerged to assist in the process of creating ontologies that satisfy the needs of representation and
appropriate use of information [
        <xref ref-type="bibr" rid="ref6">6</xref>
        ]. Thus, EO is defined as a set of activities related to the
development process, life cycle, methods, tools, and languages for the construction of ontologies.
Basically, three types of EO activities are considered: management, development and support [
        <xref ref-type="bibr" rid="ref7">7</xref>
        ].
      </p>
      <p>In other words, when working with ontology, there needs to be a development process. For the
construction of OntoNeH, the Systematic Approach for Building Ontologies (SABiO) [8] was selected,
together with a foundation ontology, the Unified Foundational Ontology (UFO) [9]. This combination
was selected by SABiO to have a solid partnership with UFO, which has already been applied in a
number of case studies. It also allows OntoNeH to be integrated in the future with other biomedical
ontologies developed with the same foundation, according to the interest of future works.</p>
      <p>There are several editors that support the construction of ontologies, and for the purpose of this
article Visual Paradigm CE was chosen, which offers free access in its community version and allows
integration with the OntoUML plugin [10], enabling the use of UFO stereotypes and meta properties.
More details on the use of SABiO, UFO, and OntoUML are discussed in the next section.
2.1. SABiO
SABiO is a systematic approach composed of development and support activities, as shown in Figure
1.</p>
      <sec id="sec-2-1">
        <title>The activities carried out in the construction of OntoNeH are described below.</title>
        <p>The first activity was the Purpose Identification and Requirements Elicitation, where initially the
identification of uses and purposes of ontology was carried out, followed by the elicitation of the
requirements. Functional requirements refer to the content to be represented by the ontology and
should be written in the form of Competency Questions (CQs). These refer to the questions that the
ontology must be able to answer, through which it is possible to achieve an effective way to
determine its scope, as well as a way to evaluate it [8]. Table 1 presents some of OntoNeH's CQs. In
the non-functional requirements, there are those of interoperability, where OntoNeH was based on
a specific foundational ontology, the UFO, which will allow and facilitate its integration with other
existing ontologies.</p>
      </sec>
      <sec id="sec-2-2">
        <title>Justification of Interest</title>
        <p>Cancer staging is extremely important as it provides
crucial information about the extent and severity of the
disease, guiding diagnosis, treatment, and prognosis.</p>
        <p>Understanding what cancer is, is essential for
comprehending one of the main causes of death in the
world and for promoting prevention, early diagnosis,
and appropriate treatment.</p>
        <p>Knowing the different types of blood cancer is crucial for
diagnosis, treatment, and proper prognosis of the
disease.</p>
        <p>Knowing how cancer is diagnosed is essential to
ensuring quick and effective treatment, in addition to
improving the chances of cure or disease control.</p>
        <p>Based on the CQs, in the Capture and Formalization activity, the domain conceptualization was
captured, resulting in conceptual modeling, where the main concepts and relevant relationships of
the domain were identified, as well as the glossary of terms3. As suggested by SABiO, the OntoUML
modeling language was used.</p>
        <p>In the support process, the Knowledge Acquisition was highlighted, in which various documents
were used to study the domain, as well as the exchange of knowledge with a specialist in the area.
This stage was very time-consuming, having been the most costly in the construction of OntoNeH;
as for Reuse, the reuse of OntoSaúde was made - whose objective is to present a conceptual model
that describes a fragment of the Collective Health domain and characterizes the relationships of a
2 The meaning of the acronyms are in Figure 2.
3 The glossary of terms can be found on GitHub at https://github.com/VanderleiaFranca/OntoNeH-ONTOBRAS_2024.
person and their possible health problems [11], which allows standardizing and integrating the
ontology developed here with future works, as well as taking advantage of existing terms such as
Person, Health Problem, Disease, Symptom and Treatment; Documentation, in which the results of
the development of the ontology were documented, occurred in parallel with the other processes;
and, finally, an Evaluation was carried out that checked whether the model has the appropriate
quality. Its focus was on the technical review, in which the authors discussed the developed model
at length. Unfortunately, there was no appropriate opportunity to work with experts in the health
area, only a brief exchange of ideas and review of the theoretical framework of the domain.
2.2. UFO
The Unified Foundational Ontology (UFO) provides guidelines for the development of other
ontologies, being a high-quality ontology applied in the development of domain ontologies [12].</p>
        <p>UFO is divided into three aspects: UFO-A (Ontology of Endurants), UFO-B (Ontology of Perdurants)
and UFO-C (Ontology of Social and Intentional Entities) [13]. In OntoNeH, UFO-A was used, which is
based on endurantes, or continuantes, which are entities that do not change their essence over time,
that is, they preserve their identity even with the changes that occur during the period of their
existence. It deals with issues such as: types and their instances; objects and their properties;
relationship between entity and classification; distinctions between types and their relations [9].</p>
        <p>Some of the UFO stereotypes used to construct OntoNeH are: kind, which provides a principle
of identity for its instances, being responsible for structuring the taxonomy representing the domain
- Person, Disease and Cell; subkind, a specialization of kind - Female, Hodgkin's Lymphoma, and
Stem Cell are specializations of Person, Disease, and Cell, respectively; phase is temporal, that is, it
is characterized by a passing phase - Adult, Elderly, Healthy and Unhealthy; and category, which
does not provide a principle of identity and encompasses entities of different species, with essential
characteristics in common - Symptom B which encompasses Fever &gt; 38º (quality), Weight Loss
&gt;10% in 6 Months (quality) and Night sweats (mode).</p>
        <sec id="sec-2-2-1">
          <title>2.3. OntoUML</title>
          <p>OntoUML, the Unified Ontology Modeling Language, was conceived as a well-grounded
ontologically based version of a UML 2.0 fragment [14]. The language was constructed following a
process in which the UML 2.0 metamodel is repaired to ensure an isomorphism in its mapping to the
structure defined by the UFO-A foundation ontology; Through formal constraints incorporated into
the meta-model of language, the axiomatization of ontology is transferred to it. Thus, OntoUML
serves as an engineering tool that enables the use of formal ontological theory in the construction of
conceptual and domain models, since it is a language with formal semantics of the real world
explicitly defined [9].</p>
          <p>The modeling language editor used to build the models was Visual Paradigm, which provides
both more formal modeling and casual drawing capabilities, due to the set of design, analysis, and
management tools that are provided. Its community version allows free license use [15]. It also allows
the installation of the OntoUML plug-in, which enables the use of stereotypes and metaproperties of
the language in class diagrams and even the verification and transformation of models [16].</p>
        </sec>
      </sec>
    </sec>
    <sec id="sec-3">
      <title>3. The Health Domain</title>
      <p>In 1946, the World Health Organization (WHO) defined health as "a state of complete physical,
mental and social well-being and not just the absence of disease or infirmity" [17], and its
maintenance is fundamental for a full life. However, numerous diseases pose challenges to global
health, and among them, cancer emerges as a leading cause of morbidity and mortality. Among the
various types of cancer, those related to blood, known as hematological cancer, which encompasses
diseases such as leukemia, lymphoma, and myeloma, stand out. A deep understanding of these
conditions is crucial for advances in prevention, early detection, and treatment, thus contributing to
the promotion of health and quality of life.</p>
      <sec id="sec-3-1">
        <title>3.1. Neoplasm</title>
        <p>
          Most normal cells of a living being grow, multiply and die in an orderly manner, in a continuous and
natural process - cell proliferation - however, not all are the same. Some never divide, such as
neurons; others, such as the cells of epithelial tissue, divide rapidly and continuously. Cell
proliferation is an inherent characteristic of cells and does not necessarily imply the presence of
malignancy (some health problem), and may simply respond to the specific needs of the different
tissues of the body [
          <xref ref-type="bibr" rid="ref1">1</xref>
          ].
        </p>
        <p>
          Cell proliferation can be controlled or uncontrolled. In controlled growth, there is a localized and
self-limited increase in the number of cells of normal tissues that form an organism, caused by
physiological or pathological stimuli. In it, the cells are normal or with small changes in their shape
and function, and may be the same or different from the tissue in which they are installed. The effect
is reversible after the end of the stimuli that caused it [
          <xref ref-type="bibr" rid="ref1">1</xref>
          ].
        </p>
        <p>Disordered, or uncontrolled, and autonomous growth of cells, on the other hand, results in a
progressive accumulation of neoplastic or tumor cells, which produces a more or less voluminous
mass, which is called tumor. Tumors deform, compress, or, depending on the speed of their growth,
destroy the organ in which they originate. In addition, tumor cells can infiltrate through the
interstices of the organs, reaching the blood and lymphatic circulation and being transported to other
organs, where they will grow and form new tumor masses, called metastases [18].</p>
        <p>Neoplasms (tumors) can be benign or malignant and their proper classification considers as main
characteristics: cell differentiation and anaplasia; tumor growth speed; local invasion and metastasis.
This differentiation refers to how similar the tumor parenchyma cell4 is to the normal parenchymal
ancestor cell. Cases in which the cells of the tumor parenchyma are very differentiated and look very
similar to their normal counterparts, making it difficult to distinguish normal cells from tumor cells.
Thus, although there is accelerated multiplication of tumor cells, reproduction is limited and occurs
in such a way that the cells that derive from it have enough time to differentiate to present a
functional configuration similar to normal. Cases in which the process of cell multiplication is so fast
and aggressive that it does not allow proper cell differentiation, characterize malignant tumors. This
cellular indifferentiation of tumor cells is called anaplasia, and tumors that have this characteristic
are called anaplastic tumors [18].</p>
        <p>
          Cancer is a malignant neoplasm and its formation process is called carcinogenesis or oncogenesis.
The cumulative effects of different carcinogens or carcinogens are responsible for tumor initiation,
promotion, progression, and inhibition. However, the individual characteristics of each person
should not be left aside, which facilitate or hinder the installation of cell damage [
          <xref ref-type="bibr" rid="ref1">1</xref>
          ].
        </p>
      </sec>
      <sec id="sec-3-2">
        <title>3.2. The Blood</title>
        <p>Considered a special type of connective tissue, blood is divided into two parts: plasma and the
figurative elements of blood, or blood tissue cells. In it, the cells of the blood tissue are separated by
a large amount of extracellular matrix, the plasma [19], which is basically composed of water,
carbohydrates, proteins, lipids, electrolytes, and salts [20].</p>
        <p>All blood cells originate from a single bone marrow's cell type, pluripotent stem cells. The fates
of the cells originated by the stem cells are: self-renewal - they remain as stem cells; and
differentiation, in which they diversify into cell types with characteristic specificities, that is, they
transform into other cell types [19].</p>
        <p>When they multiply, pluripotent stem cells originate: lymphoid cells, which give rise to
lymphocytes, which include the so-called B cells and T cells; and myeloid cells, which form
erythrocytes (red blood cells), leukocytes (white blood cells), and platelets, which are the smallest
blood cells [19]. Produced in the bone marrow and released daily into the circulation, blood cells are
specialized cells - cells that have undergone differentiation [20]. And being cells, they are also subject
to the development of neoplasms.
4The parenchyma is represented by the set of "functional" cells and tissues, that is, those that perform the specific functions
that characterize a certain organ. In the case of tumors, the parenchyma is made up of neoplastic cells [18].</p>
      </sec>
      <sec id="sec-3-3">
        <title>3.3. Hematologic malignant neoplasms</title>
        <p>Hematological malignant neoplasms, or blood cancer, are a category of onco-hematological diseases
that affect the bone marrow, blood, and lymphatic system5. In general, the types of blood cancer are
related to the type of cell in which the malignant neoplasm emerged. They can be classified into:
leukemia, lymphoma and myeloma, or multiple myeloma.</p>
        <p>Leukemia is a clonal disease that involves bone marrow progenitor cells. Depending on the
duplication rate of the neoplastic clone, they are classified as acute or chronic, which in turn are
classified as myeloid or lymphoid leukemias, depending on the clonal involvement in cells of the
myeloid or lymphoid lineage. Thus, the subtypes of leukemia are determined: Acute Myeloid
Leukemia (AML), Acute Lymphocytic Leukemia (ALL), Chronic Myeloid Leukemia (CML) and
Chronic Lymphocytic Leukemia (CLL) [21].</p>
        <p>Multiple Myeloma (MM) is a type of blood cancer that develops due to genetic alterations of a
neoplastic clonal B lymphocyte, which lead to the accumulation of malignant plasma cells [22]. These
accumulate in the bone marrow forming plasmacytomas, which can grow inside or outside the bone,
that is, intramedullary or extramedullary, respectively. When several plasmacytomas are found
inside and outside the bone, MM is characterized [23].</p>
        <p>Lymphomas are a group of diseases that are characterized by the appearance of malignant
lymphocytes that accumulate in the lymph nodes, producing a clinical condition called adenopathy.
They are subdivided into Hodgkin's Lymphoma (HL) and Non-Hodgkin's Lymphoma (NHL) [24].</p>
        <p>Non-Hodgkin's Lymphomas comprise a wide and heterogeneous group of lymphoid neoplasms
[22], and are due to genetic damage during lymphoid cell maturation [21]. They originate from
abnormalities that occur at any stage of the development of B or T lymphoid cells, which give rise
to neoplastic clones with distinct molecular, genotypic, and phenotypic characteristics, leading to
distinct histological subtypes [22].</p>
        <p>Hodgkin's Lymphoma, on the other hand, is a clonal lymphoid malignant neoplasm, resulting
from a malignant clone of cells called Reed-Sternberg cells [21], restricted mainly to lymph nodes
and lymphoid organs [25]. In 2008 and 2014, respectively, the WHO classified and reviewed
Hodgkin's Lymphoma into two groups: Classical Hodgkin Lymphoma (CHL) and Nodular
Lymphocyte-predominant Hodgkin Lymphoma (NLPHL). The LHC is subdivided into four
histological subtypes: nodular sclerosis, mixed cellularity, lymphocyte predominance, and
lymphocyte depletion [21]., which are defined based on the relative proportions of Reed-Sternberg
cells, lymphocytes, and fibrosis. NLPHL differs from CHL by the absence of Reed-Sternberg cells and
the predominant presence of lymphocyte cells, which are morphological variants of Reed-Sternberg
cells with expression of B-lineage markers [26].</p>
        <p>The diagnosis of HL is made by histopathological evaluation of the affected lymph node, via
excisional biopsy. An entire lymph node is preferably removed for evaluation, and biopsy of inguinal
lymph nodes should be avoided if other peripheral lymph nodes are affected. If there are only organs
or deep lymph nodes, it is recommended to perform thoracoscopy, laparoscopy, laparotomy, or
image-guided biopsy [21].</p>
        <p>It is important to confirm the diagnosis with immunophenotype study by immunohistochemistry,
as it allows the subclassification of Lymphoma into classic type or nodular lymphocytic
predominance [27], in which the presence of Hodgkin and Reed-Sternberg cells is defining of CLH,
while the detection of lymphocyte predominant cells (LP) is necessary for the diagnosis of NLPHL
[28]. This distinction is important, as NLPHL and CLH have different natural histories, prognoses,
and treatments [29].</p>
        <p>Cancer staging is done by clinical, laboratory and imaging tests [24], and is performed after
diagnosis, and is used to define the extent of the disease, as well as the presence or absence of factors
that affect prognosis. Thus, it is possible to attribute a stage to the disease [25].
5It is a system of specialized vessels and organs that, like the venous system, transports fluids throughout the body and
regulates their quantity. It is also a vital part of the immune system, which helps fight infections and diseases [30].</p>
      </sec>
    </sec>
    <sec id="sec-4">
      <title>4. OntoNeH</title>
      <sec id="sec-4-1">
        <title>4.1. OntoNeH Graphical Representation</title>
        <p>A graphical representation is essential to illustrate the relationships between entities and their
characteristics in a clear and concise way, and has been applied in OntoNeH to facilitate the
visualization and understanding of the complex structures of the Oncohematology domain.</p>
      </sec>
      <sec id="sec-4-2">
        <title>4.1.1. Overview</title>
        <p>The Purpose of OntoNeH is to capture, represent and organize knowledge related to
Oncohematology; facilitate the integration of information and data from different sources and
systems related to hematological neoplasms; and to promote a consistent and standardized structure
to describe concepts and relationships, making it possible to integrate and expand them to other
ontologies in the Healthcare domain.</p>
        <p>As for Use, the proposed ontology will facilitate the dissemination and understanding of
knowledge, serving as an educational tool for training and qualification of professionals, students
and researchers in the field; it can be used in the implementation and development of computational
systems and tools to support clinical decision-making that use ontology to offer evidence-based
recommendations.</p>
        <p>OntoNeH has six sub-ontologies, as identified in Figure 2, which presents a package diagram with
the overview of the ontology, its sub-ontologies and relationships.</p>
        <p>The packages were chosen in order to follow the natural process that goes from the formation of
the disease to its treatment. In this article, the sub-ontologies Disease, Neoplasm, Oncohematology
and Diagnosis are addressed.</p>
        <p>A color legend was created to identify the origin of the terms in the different diagrams, since each
package (a sub-ontology) is represented by a color and the terms from it are marked with this color.</p>
      </sec>
      <sec id="sec-4-3">
        <title>4.1.2. Disease Sub-ontology</title>
        <p>The Disease sub-ontology, whose diagram is in Figure 3, reuses OntoSaúde through more generic
terms of a Disease, in addition to preparing the integration with other ontologies that are also based
on OntoSaúde. Since they are related works and ontological models with the same foundation, that
is, UFO, the changes proposed in OntoSaúde are an evolution of it, visualized from its integration
with other ontologies, without altering its essence or the commitments made.
6 Images of OntoNeH’s subontologies can be found on GitHub at https://github.com/VanderleiaFranca/OntoNeH-ONTOB
RAS_2024.</p>
        <p>A Person can be a Man or a Woman and is at a certain stage of life, whether they are a Child,
Adolescent, Adult or Elderly. A Person is formed by Body and Mind. The Cell is a component of the
Body and undergoes Genetic Mutation, which in turn causes Cancer, which is a type of Disease. Even
more, a Person can be Healthy - Not have a Health Problem, or Have a Health Problem under Control,
and these concepts are characterized by a Manifested Health Problem. A Person can also be
Unhealthy when they have a Health Problem, be it an Accident or an Illness.</p>
        <p>Answering DS_CQ1, Staging describes the extent of Cancer, being an event performed after
Diagnosis, and which explains a Health Problem. It will also assist in defining the Treatment strategy.
In turn, Symptom is a factor used to determine Staging, and together with the Sign are Characteristic
of a Disease.</p>
        <p>It is worth highlighting a change identified in OntoSaúde, based on the needs of OntoNeH: the
addition of the concept of Manifested Health Problem, which is a characteristic
(characterization)of a Person, and a manifestation (manifestation) of a Health
Problem, which allowed a better understanding of the relationships between the concepts. Changes
have also been made to the stereotypes of some concepts to better suit, such as Symptom, from mode
to category, since the nature of them is different types of things.</p>
      </sec>
      <sec id="sec-4-4">
        <title>4.1.3. Neoplasm Sub-ontology</title>
        <p>Figure 4 presents the Neoplasm sub-ontology, which represents the process of formation of a
neoplasm, and its distinction from cancer, which is a malignant neoplasm.</p>
        <p>Bone Marrow is composed of Stem Cells, which can undergo Self-Correction or Differentiation.
One of its subtypes is the Pluripotent Stem Cell, which when it undergoes Differentiation is said to
be a Differentiated Pluripotent Stem Cell, giving rise to the Myeloid Cell and Lymphoid Cell. In turn,
these can give rise to the Leukocyte, Erythrocyte, Platelet, B Lymphocyte and T Lymphocyte
subtypes. These subtypes are part of the Figured Element of Blood, which is produced in the Bone
Marrow. Another component of Blood is Plasma, composed of Electrolyte, Lipid, Carbohydrate,
Water, Protein and Salts.</p>
        <p>A Cell undergoes Cell Multiplication. When this is a Controlled Multiplication it is said to be a
Normal Cell. However, when Uncontrolled Multiplication occurs, it is classified as a Cell with
Mutation, which is part of a Neoplasm. This can specialize in Benign Neoplasm, which occurs when
there is Negative Capacity, that is, when the Cell with Mutation does not have Ability to Invade
Neighboring Tissue; and in Malignant Neoplasm, also called Cancer, a type of Neoplasm (or Tumor),
formed by a Cell with Mutation that results from Cell Multiplication in an uncontrolled way
(Uncontrolled Multiplication) and is characterized by the Positive Ability to invade neighboring
tissue (Ability to Invade Neighboring Tissue), and that’s the answer to NeS_QC2. When Malignant
Neoplasm occurs in the Blood it is called Hematological Neoplasm.</p>
        <p>Several changes occurred in the sub-ontology during its development. Concepts were eliminated,
such as the division of Bone Marrow into red marrow and yellow marrow, being replaced by Stem
Cell, in a componentOf relation of the marrow - which allowed greater fluidity and compatibility
with the concept of Pluripotent Stem Cell.</p>
        <p>One point that generated intense debate was the choice of the UFO stereotypes of Positive Ability
and Negative Ability. At first, the instinct was to classify them as phase, as their concepts may
instinctively suggest, in the same way that occurred with the concepts of Not Having a Health
Problem and Having a Health Problem under Control, Healthy and Unhealthy in the Disease
subontology. However, a benign nodule will remain benign, that is, it does not become malignant [31],
and so there is no possibility of change between the Positive Capacity and Negative Capacity, as a
phase would ask – even if the change does not occur, the possibility should exist. It was then
decided to use the mode stereotype, as they are specializations of Ability to Invade Neighboring
Tissue, a characteristic of the Cell with Mutation.</p>
      </sec>
      <sec id="sec-4-5">
        <title>4.1.4. Oncohematology Sub-ontology</title>
        <p>Figure 5 represents the Oncohematology sub-ontology, which brings the different types of cancer in
the blood.</p>
        <p>A Hematological Neoplasm can specialize in Leukemia, Lymphoma or Myeloma, which is
equivalent to Multiple Myeloma, answering OnS_QC3. In turn, Lymphoma specializes in Hodgkin's
Lymphoma, whose subtypes are Nodular Lymphocyte-predominant Hodgkin Lymphoma and
Classical Hodgkin Lymphoma, with the subtypes Nodular Sclerosis, Mixed Cellularity, Lymphocyte
Depletion and Lymphocyte-Rich; and Non-Hodgkin Lymphoma.</p>
        <p>A Leukemia can be Acute or Chronic. The first can be classified into Acute Lymphocytic
Leukemia and Acute Myeloid Leukemia. The second has associated the subtypes Chronic
Lymphocytic Leukemia and Chronic Myeloid Leukemia.</p>
        <p>Because it is a diagram that deals with the taxonomy of Hematological Neoplasms, that is, classify
the types of cancers in the blood, this was the diagram that generated the least doubts related to
modeling decisions.</p>
      </sec>
      <sec id="sec-4-6">
        <title>4.1.5. Diagnostic Sub-ontology</title>
        <p>The Risk Factor - factors whose exposure increases the probability of occurrence of the disease
partially explains the genesis of Lymphoma, and among them are: Exposure to Toxic Agent;
Radiation Exposure; Organ Transplant; and certain diseases such as Autoimmune Disease,
Immunodeficiency, and Viral Infection, which can be HIV, HTLV-I/II, and Epstein-Barr Virus.</p>
        <p>Hodgkin's Lymphoma has some characteristics as Sign, including Adenopathy, Splenomegaly
and Hepatomegaly. As Symptom, the following are identified, among others: Chest Pain, Cough,
Anemia, Dyspnea and Loss &gt; 10% of Weight in 6 Months. Hodgkin's Lymphoma is identified through
a Diagnosis, which is obtained by performing a Biopsy, that looks for the Presence of Reed-Sternberg
Cell, and if it’s positive, indicate Classical Hodgkin Lymphoma and if it’s negative, Absence of
ReedSternberg Cell, indicate Nodular Lymphocyte-predominant Hodgkin Lymphoma, as an answer for
DiS_CQ4.</p>
        <p>After the Diagnosis, Staging occurs, which is based on Anatomy as a means of classification, as
well as on Modifier, which include: A; B, which gives its name to Symptom B; X; and E. Anatomy
includes the Diaphragm Side and the Lymph Node Region. Staging is performed with the help of
Exam, which can be Clinical Exam, Imaging Exam and Laboratory Exam, in which a Biopsy is a
specialization of the latter.</p>
        <p>This sub-ontology initially included the details of staging and treatment, but for better
visualization and representation of the relationships they were separated into different
subontologies. One issue highlighted, and much discussed, was about the concept of Staging - in the
beginning the staging classifications (stages I, II, III and IV) were presented as specializations of the
staging itself, but after questioning who has stage, it was seen that the classifications are related to
the disease, as it is the disease that specializes them.</p>
      </sec>
    </sec>
    <sec id="sec-5">
      <title>5. Conclusion</title>
      <p>OntoNeH is a reference ontology in the field of Health, focusing on the oncology sub-area of blood
malignancies, i.e., blood neoplasms. It proposes to establish a basis for concepts about cancers that
affect the blood such as myeloma, leukemia and lymphoma, the latter being the most detailed
fragment in this text, especially Hodgkin's Lymphoma and its Classic subtype.</p>
      <p>General concepts of the domain and subsequent specification for the characteristics of Hodgkin's
Lymphoma were addressed and OntoSaúde concepts were reused, which contributes to the
standardization of OntoNeH and integration with other ontologies, such as OntoTB [32] and OntoHI
[33], which are related works, making use of the same methodology and rationale, SABiO and UFO,
respectively. This allows the model to be prepared to address other diseases. Thus, it is expected that
future works can expand the study of the disease and create ontologies for other hematological
neoplasms or even solid cancers; to publish expanded OntoNeH, adding the sub-ontologies that were
not exposed here; to map the reference ontology to operational ontology, making it
machineprocessable; conduct a search for ontological models in the cancer domain that use foundations other
than UFO, seeking potential conceptual integrations. It is recommended that in the future the studies
would be made with the assistance of a professional in the field of the domain, hematologist or
oncologist, which will allow a more consistent work in accordance with reality in the verification of
the information collected and a final work validated in a broader and more complete way, since here
this was restricted to a discussion between the authors, who conducted a technical review.</p>
      <p>The use of ontologies in the field of oncology can provide significant benefits from a humanitarian
point of view. Since they allow for the semantic and structured representation of medical knowledge,
ontologies can be used to integrate and organize information coming from different sources,
ensuring that healthcare professionals have access to structured data in an appropriate way. They
can facilitate collaboration between health professionals and researchers, allowing an efficient
exchange of knowledge and data, leading to the acceleration of scientific research in the field of
cancer. This can result in the development of diagnostic support systems, enabling faster and more
accurate diagnoses, which allows for appropriate medical intervention in the early stages of the
disease. They can also be used in the creation of structured educational resources that facilitate the
understanding of concepts related to the disease, promoting awareness among health professionals,
patients and the general public, contributing to its prevention and early detection.</p>
      <p>The benefits related to the use of ontologies can also be economical. Cost reduction combined
with better treatment results due to faster and more accurate decision-making by health
professionals with the use of better tools to support clinical decision-making, which would be created
with the represented and shared knowledge provided by ontologies. The optimization of resources
invested in research and consequent discovery of new therapeutic approaches, since ontologies
facilitate the organization and categorization of information, which accelerates research processes.
A more in-depth understanding of cancer, facilitated by ontologies, can contribute to a more efficient
management of resources such as better allocation of equipment and personnel, as well as lead to an
improvement in the quality of care, resulting in improved quality of life for patients, potentially
reducing costs associated with complications and hospital readmissions. On the other hand, the
standardization in the representation of concepts, provided by ontologies, facilitates communication
between health systems and institutions, leading to a reduction in the redundancy of information,
minimization of errors and improvement in the efficiency of processes, which can have positive
implications for operating costs.</p>
      <p>The large amount of domain information available requires tools that speed up analysis and
improve its accuracy and understanding. In this scenario, ontologies play a fundamental role. Even
more so when fast, integrated, detailed and clear access to information is fundamental for a
professional's decision-making, such as in the treatment of a person. OntoNeH can be applied in a
variety of areas, from clinical practice to research and technological development. It can provide a
clear and structured model of knowledge capable of assisting in the teaching of health professionals
and students. In the field of research, ontology offers a standardization of the knowledge obtained in
clinical and laboratory studies, which would facilitate the comparison of data and the results of
different researches, in addition to allowing the creation of new computational models for the
analysis of large volumes of data. Integrating OntoNeH with electronic medical record systems,
decision-making support tools, and other medical software, coupled with a standardized database,
can lead to better interoperability between different hospital systems, ensuring that all data is
interpreted consistently. A database with structured information from OntoNeH can be used to build
a tool that helps to reduce the waiting lines for triage and improve its flow, especially if integrated
with OntoSaúde and expanded to other domains of neoplasms. In addition, it can be used to train
artificial intelligence (AI) and machine learning algorithms in assisted diagnosis systems, allowing
them to identify patterns and make predictions about the development of hematological
malignancies based on structured clinical data, which can lead to the creation of predictive models
and comparative studies between different types of cancer, making it possible to identify new
patterns and relationships that can be exploited for the development of more effective therapies.
[8] FALBO, Ricardo de Almeida. SABiO: Systematic approach for building ontologies. CEUR
Workshop Proceedings, 1301. 2014. Available at:
&lt;https://ceur-ws.org/Vol1301/ontocomodise2014_2.pdf&gt;. Accessed on: March 29, 2023.
[9] GUIZZARDI, Giancarlo. Ontological Foundations for Structural Conceptual Models. ISBN
90-75176-81-3, Universal Press. Enschede, The Netherlands, 2005. Available at: &lt;
https://nemo.inf.ufes.br/wp-content/papercitedata/pdf/ontological_foundations_for_structura l_conceptual_models_2005.pdf&gt;. Accessed
on: October 10, 2023.
[10] SUCHÁNEK, Marek. OntoUML specification Documentation. 2022. Available at:
&lt;https://ontouml.readthedocs.io/_/downloads/en/latest/pdf/&gt;. Accessed on: July 09, 2023.
[11] COSTA, Danielli do Reis; TEIXEIRA, Maria das Graças da S.; RISSINO, Silvia das
Dores; GUARNIER, Thayza S. O Uso da Abordagem SABiO na Construção do Overview de
OntoSaúde em Engineering Ontologies and Ontologies for Engineering. Celebrating Ricardo
FALBO’s Career. Editors: ALMEIDA, João Paulo A.; GUIZZARDI, Giancarlo. Nemo, Vitória
- ES, Brazil. 2020. Available at:
https://nemo.inf.ufes.br/wp-content/papercitedata/pdf/engineering_ontologies_
and_ontologies_for_engineering_celebrating_ricardo_falbos_career_2020.pdf&gt;. Accessed
on: June 03, 2023.
[12] GUIMARÃES, Rachel Cristina Mello; GUIZZARDI, Giancarlo;
GOTTSCHALGDUQUE, Cláudio. Nomeação de Elementos Ontológicos para Criação de Ontologias: uma
Proposta Metodológica. University of Brasilia. Brasília, 2015. Available at:
&lt;http://www.realp.unb.br/jspui/handle/10482/22049?locale=es&gt;. Accessed on: April 12,
2023.</p>
    </sec>
  </body>
  <back>
    <ref-list>
      <ref id="ref1">
        <mixed-citation>
          [1]
          <string-name>
            <surname>INCA.</surname>
          </string-name>
          <article-title>ABC do câncer: abordagens básicas para o controle do câncer</article-title>
          .
          <source>José Alencar Gomes da Silva National Cancer Institute</source>
          . 6. ed. Rio de Janeiro,
          <year>2020</year>
          . Available at: &lt; https://www.inca.gov.br/sites/ufu.sti.inca.local/files/media/document/livro-abc-6
          <article-title>-edicao2020</article-title>
          . pdf&gt;.
          <source>Accessed on: March</source>
          <volume>30</volume>
          ,
          <year>2023</year>
          .
        </mixed-citation>
      </ref>
      <ref id="ref2">
        <mixed-citation>
          [2]
          <string-name>
            <surname>INCA. Estimativa</surname>
          </string-name>
          <year>2023</year>
          : incidência de câncer no Brasil. National Cancer Institute / Ministry of Health. Rio de Janeiro,
          <year>2022</year>
          . Available at: &lt; https://www.inca.gov.br/sites/ufu.sti.inca.local/files//media/document//estimativa2023.pdf&gt;.
          <source>Accessed on: June 02</source>
          ,
          <year>2023</year>
          .
        </mixed-citation>
      </ref>
      <ref id="ref3">
        <mixed-citation>
          [3]
          <string-name>
            <surname>BORST</surname>
            ,
            <given-names>W. N.</given-names>
          </string-name>
          <article-title>Construction of Engineering Ontologies</article-title>
          . Thesis, University of Tweenty - Centre
          <source>for Telematics and Information Technology. Enschede - Nederland</source>
          ,
          <year>1997</year>
          .
        </mixed-citation>
      </ref>
      <ref id="ref4">
        <mixed-citation>
          [4]
          <string-name>
            <surname>ZENG</surname>
          </string-name>
          ,
          <string-name>
            <given-names>Marcia</given-names>
            <surname>Lei</surname>
          </string-name>
          .
          <article-title>Knowledge organization systems (KOS)</article-title>
          . Knowledge Organization, [S. l.], v.
          <volume>35</volume>
          , n.
          <issue>2-3</issue>
          , p.
          <fpage>160</fpage>
          -
          <lpage>182</lpage>
          ,
          <year>2008</year>
          . DOI:
          <volume>10</volume>
          .5771/
          <fpage>0943</fpage>
          -7444-2008-2-3-160. Available at: &lt;https://www.nomos-elibrary.de/10.5771/
          <fpage>0943</fpage>
          -7444-2008-2-3-160.pdf&gt;.
          <source>Accessed on: July 22</source>
          ,
          <year>2024</year>
          .
        </mixed-citation>
      </ref>
      <ref id="ref5">
        <mixed-citation>
          [5]
          <string-name>
            <surname>GUARINO</surname>
          </string-name>
          , Nicola.
          <source>Formal Ontologies and Information Systems</source>
          . Conference: FOIS'98 Conference At: Trento, Italy. June 1998. Available at: &lt; https://www.researchgate.net/publication/272169039_Formal_Ontologies_and_Information _Systems&gt;.
          <source>Accessed on: March</source>
          <volume>29</volume>
          ,
          <year>2023</year>
          .
        </mixed-citation>
      </ref>
      <ref id="ref6">
        <mixed-citation>
          [6]
          <string-name>
            <surname>ISOTANI</surname>
          </string-name>
          , Seiji; BITTENCOURT,
          <string-name>
            <given-names>Ig</given-names>
            <surname>Ibert</surname>
          </string-name>
          . Dados Abertos Conectados.
          <article-title>Center for Studies on Web Technology-Web.br</article-title>
          .
          <source>Novatec Publishing</source>
          ,
          <year>2015</year>
          . Available at: https://ceweb.br/livros/dados-abertos-conectados//. Accessed on: March 29,
          <year>2023</year>
          .
        </mixed-citation>
      </ref>
      <ref id="ref7">
        <mixed-citation>
          [7]
          <string-name>
            <surname>GÓMEZ-PÉREZ</surname>
            ,
            <given-names>A.</given-names>
          </string-name>
          ;
          <string-name>
            <surname>FERNANDEZ-LOPEZ</surname>
            ,
            <given-names>M.</given-names>
          </string-name>
          ;
          <string-name>
            <surname>CORCHO</surname>
            ,
            <given-names>O. Ontological</given-names>
          </string-name>
          <string-name>
            <surname>Engineering</surname>
          </string-name>
          . Springer-Verlag Berlin, Heidelberg,
          <year>2004</year>
          . ISBN:1852335513. GUIZZARDI, Giancarlo; ALMEIDA, João Paulo Andrade; GUIZZARDI,
          <string-name>
            <surname>Renata</surname>
            <given-names>S.S.; FALBO</given-names>
          </string-name>
          , Ricardo. Ontologias de Fundamentação e Modelagem Conceitual Núcleo de
          <article-title>Estudos em Modelagem Conceitual e Ontologias (NEMO)</article-title>
          . Federal University of Espírito Santo (UFES).
          <source>Vitória - ES</source>
          ,
          <year>2009</year>
          . Available at: https://nemo.inf.ufes.br/wp-content/papercitedata/pdf/ontologias_de_fundamentacao_e_modelagem_conceitual_
          <year>2009</year>
          .pdf&gt;.
          <source>Accessed on: October 10</source>
          ,
          <year>2023</year>
          .
          <source>OMG® SDO. About The Unified Modeling Language Specification Version</source>
          <volume>2</volume>
          .0.
        </mixed-citation>
      </ref>
      <ref id="ref8">
        <mixed-citation>
          <string-name>
            <given-names>Object</given-names>
            <surname>Management Group</surname>
          </string-name>
          <article-title>® (OMG®) Standards Development Organization (SDO</article-title>
          ),
          <year>2005</year>
          .
        </mixed-citation>
      </ref>
    </ref-list>
  </back>
</article>